Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Acceleron Pharma Inc. (NASDAQ: XLRN).

Full DD Report for XLRN

You must become a subscriber to view this report.

Recent News from (NASDAQ: XLRN)

Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31
Acceleron to Participate in Three Upcoming Healthcare Investor Conferences
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming healthcare investor conferences. Conference D...
Source: Business Wire
Date: September, 04 2018 07:00
Acceleron's Luspatercept: IOMachine Focused On NDA
On TPT member request, we ran Acceleron Pharma ( XLRN ) through the IOMachine , July 2nd 2018. If you recall, the IOMachine (Copyright applied: please do not copy) performs a four-factor test on a stock and comes up with a buy/sell investibility opinion. These four factors are upcoming cataly...
Source: SeekingAlpha
Date: September, 03 2018 08:00
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516...
Source: SeekingAlpha
Date: September, 01 2018 05:42
Pfizer mid-stage flop with domagrozumab in DMD another setback for myostatin inhibitors - Endpoints News
Endpoints News' John Carroll reports that Pfizer's failure with domagrozumab in Duchenne muscular dystrophy (DMD) is another black eye for myostatin inhibitors for muscle wasting disorders. More news on: Novartis AG, Amgen Inc., Atara Biotherapeutics, Healthcare stocks news, Read mor...
Source: SeekingAlpha
Date: August, 30 2018 12:36
Celgene Has Emerged As An Attractive Buy Opportunity In 2018
The last year has been pretty harsh for Celgene ( CELG ), as concerns related to Revlimid's patent expiry have gradually mounted. And these worries have eclipsed the investor sentiment to this extent that people seem to have forgotten some very basic facts about Celgene. The concerns about Rev...
Source: SeekingAlpha
Date: August, 10 2018 09:29
Acceleron Pharma Inc. 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 03 2018 15:18
Acceleron Pharma, Inc. (XLRN) CEO Habib Dable on Q2 2018 Results - Earnings Call Transcript
Acceleron Pharma, Inc. (XLRN) Q2 2018 Earnings Conference Call August 02, 2018, 17:00 ET Executives Todd James - VP, IR & Corporate Communications Habib Dable - CEO, President & Director Robert Zeldin - Chief Medical Officer Kevin McLaughlin - CFO, Senior VP & Treas...
Source: SeekingAlpha
Date: August, 02 2018 22:59
Acceleron Pharma beats by $0.01, misses on revenue
Acceleron Pharma (NASDAQ: XLRN ): Q2 EPS of -$0.63 beats by $0.01 . More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 02 2018 16:22
Acceleron Reports Second Quarter 2018 Operating and Financial Results
– MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints – – ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway – – PULSAR Phase 2 trial initiated w...
Source: Business Wire
Date: August, 02 2018 16:05


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on XLRN.

About Acceleron Pharma Inc. (NASDAQ: XLRN)

Logo for Acceleron Pharma Inc. (NASDAQ: XLRN)

Not available


Contact Information



Current Share Structure

  • Market Cap: $1,616,918,572 - 05/11/2018
  • Issue and Outstanding: 45,419,061 - 01/31/2018


Recent Filings from (NASDAQ: XLRN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 13 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018



Daily Technical Chart for (NASDAQ: XLRN)

Daily Technical Chart for (NASDAQ: XLRN)

Stay tuned for daily updates and more on (NASDAQ: XLRN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: XLRN)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in XLRN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of XLRN and does not buy, sell, or trade any shares of XLRN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: